EE+ POEM Archive
Evolocumab reduces adverse cardiovascular events in high-risk adults unable to meet their lipid goals with statin therapy (VESALIUS-CV)
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Barry, Henry, et al., editors. "Evolocumab Reduces Adverse Cardiovascular Events in High-risk Adults Unable to Meet Their Lipid Goals With Statin Therapy (VESALIUS-CV)." EE+ POEM Archive, John Wiley & Sons, 2026. Evidence Central, evidence.unboundmedicine.com/evidence/view/infoPOEMs/3377663/all/Evolocumab_reduces_adverse_cardiovascular_events_in_high_risk_adults_unable_to_meet_their_lipid_goals_with_statin_therapy__VESALIUS_CV_.
Evolocumab reduces adverse cardiovascular events in high-risk adults unable to meet their lipid goals with statin therapy (VESALIUS-CV). In: Barry HH, Ebell MHM, Shaughnessy AFA, et al, eds. EE+ POEM Archive. John Wiley & Sons; 2026. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/3377663/all/Evolocumab_reduces_adverse_cardiovascular_events_in_high_risk_adults_unable_to_meet_their_lipid_goals_with_statin_therapy__VESALIUS_CV_. Accessed June 15, 2026.
Evolocumab reduces adverse cardiovascular events in high-risk adults unable to meet their lipid goals with statin therapy (VESALIUS-CV). (2026). In Barry, H., Ebell, M. H., Shaughnessy, A. F., & Slawson, D. C. (Eds.), EE+ POEM Archive. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/3377663/all/Evolocumab_reduces_adverse_cardiovascular_events_in_high_risk_adults_unable_to_meet_their_lipid_goals_with_statin_therapy__VESALIUS_CV_
Evolocumab Reduces Adverse Cardiovascular Events in High-risk Adults Unable to Meet Their Lipid Goals With Statin Therapy (VESALIUS-CV) [Internet]. In: Barry HH, Ebell MHM, Shaughnessy AFA, et al, eds. EE+ POEM Archive. John Wiley & Sons; 2026. [cited 2026 June 15]. Available from: https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/3377663/all/Evolocumab_reduces_adverse_cardiovascular_events_in_high_risk_adults_unable_to_meet_their_lipid_goals_with_statin_therapy__VESALIUS_CV_.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Evolocumab reduces adverse cardiovascular events in high-risk adults unable to meet their lipid goals with statin therapy (VESALIUS-CV)
ID - 3377663
ED - Barry,Henry,
ED - Ebell,Mark H,
ED - Shaughnessy,Allen F,
ED - Slawson,David C,
BT - EE+ POEM Archive
UR - https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/3377663/all/Evolocumab_reduces_adverse_cardiovascular_events_in_high_risk_adults_unable_to_meet_their_lipid_goals_with_statin_therapy__VESALIUS_CV_
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -
